Key Players
Competitive Landscape
Oncology precision medicine competitors include genomic profiling platforms, companion diagnostic developers and biomarker-led therapy companies. Suppliers compete through assay performance, clinical actionability and turnaround support within a defined treatment pathway.
Investment has shifted toward platforms that connect profiling with monitoring. Roche acquired SAGA Diagnostics in May 2026 and gained the Pathlight molecular residual disease platform, while Thermo Fisher Scientific and Illumina expanded companion diagnostic routes in late 2025. Buyers now assess whether a supplier can support one treatment decision from sample handling through clinical follow-up.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Roche acquired SAGA Diagnostics and Pathlight in May 2026 | MRD monitoring after treatment | Profiling platforms add MRD | Treatment monitoring |
| Thermo Fisher gained FDA approval for an Oncomine NSCLC companion diagnostic in November 2025 | Validated test-to-therapy links | NGS panels gain drug-specific claims | NSCLC laboratory testing |
| Illumina announced KRAS companion diagnostic partnerships in September 2025 | Consistent eligibility testing | Distributable CGP expands CDx coverage | Pharma collaboration and global deployment |
AstraZeneca PLC, Pfizer Inc., Guardant Health, Inc., QIAGEN N.V., Novartis AG and Abbott Laboratories remain active across biomarker-linked therapy and diagnostic workflows outside the three mapped developments.
Source: Future Market Insights, Oncology Precision Medicine Market report, 2026-2036.
Roche, Thermo Fisher Scientific and Illumina demonstrate different routes to clinical action, while the wider group is compared on diagnostic reach and treatment relevance. Approvals and registrations remain with the named product, legal entity or operating site.
Which companies connect genomic profiling with treatment selection?
Roche and Foundation Medicine connect tissue and liquid genomic profiling with therapy selection, while Thermo Fisher Scientific and Illumina supply NGS platforms used in companion diagnostic development.
Which companies extend precision oncology into liquid biopsy and MRD?
Guardant Health supports circulating tumor DNA testing for therapy decisions and monitoring. Roche gained the Pathlight molecular residual disease platform through its SAGA Diagnostics acquisition.
Which companies develop biomarker-led oncology therapeutics?
AstraZeneca PLC, Pfizer Inc. and Novartis AG develop oncology medicines whose use can depend on biomarker testing, patient selection or a defined molecular pathway.
Which companies support hospital and laboratory workflows?
Thermo Fisher Scientific, Illumina, QIAGEN and Abbott Laboratories provide instruments, assays or molecular testing capability used by diagnostic laboratories and hospital-based oncology programs.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Roche Holding AG | Global precision oncology | Foundation Medicine profiling and Pathlight MRD |
| Thermo Fisher Scientific Inc. | Laboratory platform | Oncomine NGS and PCR companion diagnostics |
| Illumina, Inc. | NGS platform | TruSight Oncology and companion diagnostic development |
| AstraZeneca PLC | Oncology therapeutics | Biomarker-led therapies and computational pathology |
| Pfizer Inc. | Oncology therapeutics | Targeted therapies supported by biomarker testing |
| Guardant Health, Inc. | Liquid biopsy | ctDNA profiling and MRD monitoring |
| QIAGEN N.V. | Molecular diagnostics | PCR, digital PCR and companion diagnostics |
| Foundation Medicine, Inc. | Genomic profiling | Tissue and liquid genomic profiling |
| Novartis AG | Precision oncology | Targeted medicines and radioligand therapy |
| Abbott Laboratories | Diagnostics | Molecular cancer testing and early detection |
Research Methodology
The comparison describes market structure rather than revenue leadership. Inclusion requires official evidence of products, approvals or operating scope within oncology precision medicine. Regulatory records, filings and company announcements establish current capability. Geographic claims record documented presence, while 2026 technology shares remain FMI estimates. The evidence does not imply group-wide certification or market-share leadership.
